TY - JOUR
T1 - Determinants of the access to remote specialised services provided by national sarcoma reference centres
AU - Fayet, Yohan
AU - Tétreau, Raphaël
AU - Honoré, Charles
AU - Le Nail, Louis Romée
AU - Dalban, Cécile
AU - Gouin, François
AU - Causeret, Sylvain
AU - Piperno-Neumann, Sophie
AU - Mathoulin-Pelissier, Simone
AU - Karanian, Marie
AU - Italiano, Antoine
AU - Chaigneau, Loïc
AU - Gantzer, Justine
AU - Bertucci, François
AU - Ropars, Mickael
AU - Saada-Bouzid, Esma
AU - Cordoba, Abel
AU - Ruzic, Jean Christophe
AU - Varatharajah, Sharmini
AU - Ducimetière, Françoise
AU - Chabaud, Sylvie
AU - Dubray-Longeras, Pascale
AU - Fiorenza, Fabrice
AU - De Percin, Sixtine
AU - Lebbé, Céleste
AU - Soibinet, Pauline
AU - Michelin, Paul
AU - Rios, Maria
AU - Farsi, Fadila
AU - Penel, Nicolas
AU - Bompas, Emmanuelle
AU - Duffaud, Florence
AU - Chevreau, Christine
AU - Le Cesne, Axel
AU - Blay, Jean Yves
AU - Le Loarer, François
AU - Ray-Coquard, Isabelle
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients. Methods: Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery. Results: Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities. Conclusions: In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks’ organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.
AB - Background: Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients. Methods: Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery. Results: Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities. Conclusions: In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks’ organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.
KW - Cancer care accessibility
KW - Cancer inequalities
KW - Rare cancers
KW - Reference networks
KW - Sarcoma
KW - Spatial inequalities
UR - http://www.scopus.com/inward/record.url?scp=85107026657&partnerID=8YFLogxK
U2 - 10.1186/s12885-021-08393-4
DO - 10.1186/s12885-021-08393-4
M3 - Article
C2 - 34049529
AN - SCOPUS:85107026657
SN - 1471-2407
VL - 21
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 631
ER -